This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory tract | 184 |
hereditary angioedema | 103 |
epithelial cells | 98 |
inh concentrate | 93 |
chronic rhinosinusitis | 91 |
respiratory syncytial | 91 |
syncytial virus | 89 |
inh deficiency | 87 |
factor xii | 77 |
viral infection | 73 |
acute respiratory | 71 |
asthmatic patients | 64 |
immune response | 61 |
older adults | 55 |
tract infections | 55 |
allergy clin | 51 |
clin immunol | 51 |
viral infections | 51 |
type i | 44 |
airway epithelial | 43 |
severe covid | 40 |
tract infection | 40 |
common cold | 40 |
angioedema attacks | 40 |
immunol doi | 39 |
cord uid | 39 |
doc id | 39 |
inhibitor deficiency | 39 |
rhinovirus infection | 38 |
gene expression | 38 |
hereditary angioneurotic | 38 |
rsv infection | 37 |
nh gene | 36 |
elderly patients | 33 |
innate immune | 32 |
type ii | 32 |
virus infection | 32 |
first year | 32 |
type iii | 32 |
viral respiratory | 32 |
online repository | 31 |
hae attacks | 31 |
severe cases | 31 |
esterase inhibitor | 30 |
ace inhibitor | 30 |
upper respiratory | 30 |
hae type | 29 |
control subjects | 29 |
immune responses | 29 |
coronavirus disease | 28 |
inhibitor gene | 28 |
angioneurotic edema | 28 |
atopic asthma | 28 |
replacement therapy | 27 |
nasal polyps | 26 |
united states | 26 |
allergic rhinitis | 25 |
nonallergic angioedema | 25 |
asthma exacerbations | 25 |
lung function | 25 |
respiratory viruses | 25 |
converting enzyme | 25 |
respiratory viral | 24 |
tract viruses | 24 |
term prophylaxis | 24 |
adverse effects | 24 |
chronic obstructive | 23 |
attenuated androgens | 23 |
experimental rhinovirus | 23 |
maternal asthma | 23 |
emergency department | 23 |
inh function | 22 |
airway inflammation | 22 |
respiratory distress | 22 |
ace inhibitors | 22 |
vascular permeability | 22 |
laryngeal edema | 22 |
air pollution | 21 |
disease severity | 21 |
tract illness | 21 |
hereditary angio | 21 |
side effects | 20 |
critically ill | 20 |
pulmonary disease | 20 |
primary hypogammaglobulinemia | 20 |
abdominal pain | 20 |
general population | 20 |
inherited angioedema | 20 |
increased risk | 20 |
allergic disease | 20 |
specific ige | 20 |
innate immunity | 19 |
bacterial biofilm | 19 |
nitric oxide | 19 |
human nasal | 19 |
elderly asthmatic | 19 |
childhood asthma | 19 |
severe acute | 19 |
contact system | 19 |
pao fio | 19 |
clinical phenotypes | 19 |
cord blood | 19 |
table i | 18 |
tranexamic acid | 18 |
obstructive pulmonary | 18 |
influenza virus | 18 |
odds ratio | 18 |
factor xiia | 18 |
age years | 18 |
cytokine storm | 18 |
risk factors | 18 |
table ii | 18 |
distress syndrome | 18 |
lower respiratory | 18 |
allergic diseases | 17 |
acute attacks | 17 |
serum levels | 17 |
tmprss expression | 17 |
airway obstruction | 17 |
inh concentration | 17 |
bronchial epithelial | 17 |
health care | 17 |
human subjects | 17 |
respiratory syndrome | 17 |
immune system | 16 |
patients infected | 16 |
asthma control | 16 |
acute abdominal | 16 |
bradykinin receptor | 16 |
home therapy | 16 |
ace expression | 16 |
asthma symptoms | 16 |
acquired angioedema | 16 |
bronchoalveolar lavage | 16 |
upper airway | 16 |
infected patients | 15 |
airflow obstruction | 15 |
patients receiving | 15 |
hungarian hae | 15 |
plasma kallikrein | 15 |
age group | 15 |
clinical characteristics | 15 |
ige levels | 15 |
peripheral blood | 15 |
biofilm formation | 15 |
mucociliary clearance | 15 |
early childhood | 15 |
older asthmatic | 15 |
controlled trial | 15 |
allergic asthma | 15 |
cohort study | 15 |
submucosal glands | 14 |
influenza vaccine | 14 |
intensive care | 14 |
complement activation | 14 |
patients treated | 14 |
nonsevere cases | 14 |
adjusted odds | 14 |
acute attack | 14 |
epithelial cell | 14 |
nasopharyngeal microbiota | 14 |
tract viral | 14 |
may also | 14 |
rag mutations | 14 |
nasal lavage | 14 |
inflammatory response | 14 |
related angioedema | 14 |
edematous attacks | 14 |
statistically significant | 14 |
respiratory infections | 14 |
i hereditary | 14 |
local immune | 13 |
previously described | 13 |
angioneurotic oedema | 13 |
novel coronavirus | 13 |
angioedema caused | 13 |
logistic regression | 13 |
ill patients | 13 |
clinical trial | 13 |
airway hyperreactivity | 13 |
induced aris | 13 |
severe patients | 13 |
inhaled corticosteroids | 13 |
like receptor | 13 |
amino acid | 13 |
healthy controls | 13 |
environmental factors | 13 |
amino acids | 13 |
lavage fluid | 13 |
inh concentrations | 13 |
antifibrinolytic agents | 13 |
control group | 13 |
inflammatory responses | 12 |
molecular weight | 12 |
plasma concentrations | 12 |
case series | 12 |
phase ii | 12 |
pediatric patients | 12 |
human plasma | 12 |
nasal epithelial | 12 |
recurrent angioedema | 12 |
factor xia | 12 |
microbiota profiles | 12 |
human rhinovirus | 12 |
bacterial biofilms | 12 |
oxygen requirement | 12 |
high levels | 12 |
lung disease | 12 |
cell receptor | 12 |
sex hormones | 12 |
danazol treatment | 12 |
significantly higher | 12 |
chronic sinusitis | 12 |
many patients | 12 |
dominant profile | 12 |
host response | 12 |
hospitalized patients | 12 |
cell numbers | 12 |
public health | 12 |
relative abundance | 12 |
nasal swabs | 12 |
attack therapy | 12 |
angioedema associated | 12 |
clinical trials | 12 |
sinus surgery | 12 |
influenza infection | 12 |
rhinovirus colds | 12 |
reactive protein | 12 |
see table | 12 |
allergic airway | 11 |
xii activation | 11 |
several studies | 11 |
viral load | 11 |
might also | 11 |
systematic review | 11 |
endothelial cells | 11 |
aminopeptidase activity | 11 |
clinical course | 11 |
nasal secretions | 11 |
inh protein | 11 |
nonatopic asthma | 11 |
host defense | 11 |
one study | 11 |
randomized controlled | 11 |
family members | 11 |
abdominal attacks | 11 |
nucleic acid | 11 |
allergen sensitization | 11 |
heart failure | 11 |
wide range | 11 |
omenn syndrome | 11 |
mouse model | 11 |
mechanical ventilation | 11 |
oral contraception | 11 |
case reports | 11 |
plasminogen activator | 11 |
ap activity | 11 |
staphylococcus aureus | 10 |
asthma exacerbation | 10 |
receptor antagonists | 10 |
pg ml | 10 |
among infants | 10 |
sample size | 10 |
determine whether | 10 |
among patients | 10 |
genetic variant | 10 |
rag protein | 10 |
clinical symptoms | 10 |
hae center | 10 |
induced ari | 10 |
aminocaproic acid | 10 |
recent studies | 10 |
reported asthma | 10 |
significant differences | 10 |
increased levels | 10 |
present study | 10 |
severe asthma | 10 |
early life | 10 |
abdominal attack | 10 |
dendritic cells | 10 |
airway disease | 10 |
familial predisposition | 10 |
human airway | 10 |
inhibitor concentrate | 10 |
clinical manifestations | 10 |
skin prick | 10 |
informed consent | 10 |
angiotensin system | 10 |
rsv ari | 10 |
better understanding | 10 |
epithelial barrier | 10 |
syndrome coronavirus | 10 |
test results | 10 |
recombinant human | 10 |
virus categories | 10 |
viral cause | 10 |
within hours | 10 |
clinical presentation | 10 |
complement components | 10 |
asthmatic participants | 10 |
contact activation | 10 |
relative odds | 10 |
induced lrtis | 10 |
kinin inactivation | 10 |
identify patients | 10 |
nasal polyposis | 10 |
refractory crs | 10 |
adaptive immune | 9 |
rrna gene | 9 |
day intubation | 9 |
postmenopausal women | 9 |
nasal mucosa | 9 |
virus safety | 9 |
functional activity | 9 |
classical pathway | 9 |
allergen exposure | 9 |
different clinical | 9 |
baseline il | 9 |
animal models | 9 |
time pcr | 9 |
treg cells | 9 |
recombination activity | 9 |
ex vivo | 9 |
human metapneumovirus | 9 |
corticosteroid use | 9 |
bacterial infection | 9 |
department visits | 9 |
respiratory pathogens | 9 |
hae attack | 9 |
hageman factor | 9 |
inflammatory mediators | 9 |
rhinoviral infections | 9 |
mg ml | 9 |
total ige | 9 |
care unit | 9 |
prospective cohort | 9 |
young children | 9 |
plasma bradykinin | 9 |
icu admission | 9 |
patients hospitalized | 9 |
prick test | 9 |
increased expression | 9 |
clinical signs | 9 |
increased susceptibility | 9 |
angiotensin ii | 9 |
previous studies | 9 |
ifng mrna | 9 |
high il | 9 |
microbial interactions | 9 |
blood samples | 9 |
infection severity | 9 |
inflammatory cells | 9 |
bitter taste | 9 |
year follow | 9 |
viral replication | 9 |
like receptors | 9 |
weight kininogen | 9 |
respiratory virus | 9 |
objective measures | 9 |
normal range | 9 |
ill cases | 9 |
healthy control | 9 |
factor xi | 9 |
asthmatic subjects | 9 |
dependent inherited | 9 |
mononuclear cells | 9 |
mendelian randomization | 9 |
hormone replacement | 9 |
respiratory disease | 8 |
barrier function | 8 |
older patients | 8 |
inhaled corticosteroid | 8 |
respiratory failure | 8 |
immune mediators | 8 |
oral corticosteroids | 8 |
findings suggest | 8 |
even though | 8 |
vasoactive peptide | 8 |
cell surface | 8 |
propensity score | 8 |
severe bronchiolitis | 8 |
endoscopic sinus | 8 |
per month | 8 |
cytokine production | 8 |
infant respiratory | 8 |
lung injury | 8 |
increased relative | 8 |
world health | 8 |
without asthma | 8 |
cell entry | 8 |
adult patients | 8 |
genetic correlation | 8 |
blood monocytes | 8 |
natural history | 8 |
normal values | 8 |
recurrent respiratory | 8 |
respiratory infection | 8 |
lupus erythematosus | 8 |
intubation mortality | 8 |
skin test | 8 |
mast cells | 8 |
rhinovirus species | 8 |
final concentration | 8 |
healthy subjects | 8 |
taste receptor | 8 |
neutralizing antibodies | 8 |
multisystem inflammatory | 8 |
respiratory illness | 8 |
ccl mrna | 8 |
less frequently | 8 |
cell subsets | 8 |
clinical outcome | 8 |
high prevalence | 8 |
respiratory symptoms | 8 |
unpublished data | 8 |
physical performance | 8 |
older persons | 8 |
clinical features | 8 |
free peritoneal | 8 |
cardiovascular disease | 8 |
peritoneal fluid | 8 |
younger asthmatic | 8 |
angioedema patients | 8 |
phase i | 8 |
reduced expression | 8 |
target protease | 8 |
deficiency workshop | 8 |
another study | 8 |
whose mothers | 8 |
related changes | 8 |
birth weight | 8 |
induced sputum | 8 |
nasal swab | 8 |
flow cytometry | 8 |
clinical studies | 8 |
risk factor | 8 |
vasoactive peptides | 8 |
recent study | 8 |
immune cells | 8 |
atopic dermatitis | 8 |
immune function | 8 |
airway hyperresponsiveness | 8 |
asthma care | 8 |
combined immunodeficiency | 8 |
important role | 7 |
well established | 7 |
high molecular | 7 |
rsv infections | 7 |
rat brain | 7 |
severe respiratory | 7 |
cell population | 7 |
kallikrein inhibitor | 7 |
gene sequencing | 7 |
systemic lupus | 7 |
median age | 7 |
medical care | 7 |
antimicrobial proteins | 7 |
female patients | 7 |
multiple comparisons | 7 |
younger patients | 7 |
serum concentrations | 7 |
protease inhibitor | 7 |
laboratory findings | 7 |
health study | 7 |
infant dyads | 7 |
rhinoviral pcr | 7 |
may increase | 7 |
bradykinin generation | 7 |
virus infections | 7 |
intestinal wall | 7 |
health organization | 7 |
airflow limitation | 7 |
antiviral agents | 7 |
ldh level | 7 |
sinus mucosa | 7 |
severe disease | 7 |
laboratory diagnosis | 7 |
described previously | 7 |
mutation database | 7 |
congestive heart | 7 |
lavage samples | 7 |
pcr results | 7 |
study found | 7 |
alternaria species | 7 |
cytokine responses | 7 |
clinical phenotype | 7 |
many different | 7 |
binding protein | 7 |
receptor antagonist | 7 |
adenoviral infection | 7 |
factor viii | 7 |
high risk | 7 |
atopic predisposition | 7 |
acute asthma | 7 |
receptor gene | 7 |
gene use | 7 |
healthy participants | 7 |
sinonasal epithelial | 7 |
proinflammatory cytokines | 7 |
high ldh | 7 |
asthma development | 7 |
studies suggest | 7 |
danazol therapy | 7 |
upper airways | 7 |
preoperative prophylaxis | 7 |
airway epithelium | 7 |
carbohydrate groups | 7 |
higher levels | 7 |
inflammatory syndrome | 7 |
observational study | 7 |
prophylactic treatment | 7 |
junction proteins | 7 |
regression model | 7 |
national institute | 7 |
elderly patient | 7 |
mutant protein | 7 |
serum ige | 7 |
transcription factor | 7 |
angioedema attack | 7 |
fungal biofilm | 7 |
antiviral response | 7 |
two patients | 7 |
onset asthma | 7 |
serum amyloid | 7 |
serine protease | 7 |
commonly used | 7 |
infants whose | 7 |
treatment options | 7 |
higher prevalence | 7 |
maxillary sinusitis | 7 |
aging process | 7 |
factors associated | 7 |
correct diagnosis | 6 |
serum complement | 6 |
reactive site | 6 |
probable asthma | 6 |
untreated patients | 6 |
familial atopic | 6 |
may lead | 6 |
widely used | 6 |
adjusted analyses | 6 |
blood institute | 6 |
analyzed using | 6 |
smooth muscle | 6 |
primary care | 6 |
severe combined | 6 |
patients diagnosed | 6 |
also shown | 6 |
wheezing illnesses | 6 |
recombinase activity | 6 |
significantly reduced | 6 |
decreased levels | 6 |
higher risk | 6 |
tris hcl | 6 |
ii hereditary | 6 |
monoclonal antibody | 6 |
nucleotide sequence | 6 |
autoimmune diseases | 6 |
might cause | 6 |
free periods | 6 |
gc qr | 6 |
new type | 6 |
severe attacks | 6 |
severe abdominal | 6 |
virus validation | 6 |
primary immunodeficiency | 6 |
pathway activation | 6 |
apoptotic cells | 6 |
immunol volume | 6 |
angioedema may | 6 |
induced asthma | 6 |
normal subjects | 6 |
genetic variants | 6 |
total protein | 6 |
epigenetic changes | 6 |
exhaled nitric | 6 |
activated factor | 6 |
randomized clinical | 6 |
women taking | 6 |
cell types | 6 |
cell differentiation | 6 |
linkage analysis | 6 |
concerted action | 6 |
lung diseases | 6 |
care workers | 6 |
elderly persons | 6 |
pmol min | 6 |
polygenic risk | 6 |
similar results | 6 |
sputum samples | 6 |
intervention group | 6 |
aventis behring | 6 |
pattern recognition | 6 |
dyax corp | 6 |
reported maternal | 6 |
cigarette smoke | 6 |
university hospital | 6 |
lesser extent | 6 |
aminopeptidase activities | 6 |
naturally occurring | 6 |
tris buffer | 6 |
increased amounts | 6 |
intrinsic pathway | 6 |
ff complement | 6 |
day oxygen | 6 |
patients showed | 6 |
rag transcription | 6 |
associated angioedema | 6 |
ifng gene | 6 |
airway responsiveness | 6 |
inactivation pathways | 6 |
tract illnesses | 6 |
bacterial infections | 6 |
validation studies | 6 |
type inflammation | 6 |
inh mutants | 6 |
edema formation | 6 |
soluble ps | 6 |
residual rag | 6 |
patients also | 6 |
receptor editing | 6 |
applied biosystems | 6 |
radial immunodiffusion | 6 |
small sample | 6 |
psoriasis patients | 6 |
inh functional | 6 |
decreased expression | 6 |
bronchiolitis severity | 6 |
maximum survival | 6 |
well tolerated | 6 |
older age | 6 |
airway microbiota | 6 |
cystic ovaries | 6 |
respiratory allergy | 6 |
dextran sulfate | 6 |
provide evidence | 6 |
nh mutations | 6 |
immune cell | 6 |
bacterial culture | 6 |
inhibitor treatment | 6 |
diagnostic criteria | 6 |
low il | 6 |
respiratory illnesses | 6 |
may result | 6 |
immune dysregulation | 6 |
autoimmune hemolytic | 6 |
inh autoantibodies | 6 |
cardiovascular health | 6 |
national health | 6 |
serpin function | 6 |
highly sensitive | 6 |
high mortality | 6 |
lopinavir ritonavir | 6 |
categorical variables | 6 |
reactive center | 6 |
induced angioedema | 6 |
room temperature | 6 |
national heart | 6 |
study included | 6 |
asthma compared | 6 |
potential adverse | 6 |
hemolytic anemia | 6 |
cell activation | 6 |
inflammatory cytokines | 6 |
included patients | 6 |
incompletely understood | 6 |
gastrointestinal tract | 6 |
common variable | 6 |
protease inhibitors | 6 |
table iii | 6 |
month intervals | 6 |
binding lectin | 6 |
arg bradykinin | 6 |
mechanisms underlying | 6 |
definite asthma | 6 |
viral clearance | 6 |
significant difference | 6 |
natural killer | 6 |
healthy adults | 6 |
also increased | 6 |
antimicrobial peptides | 6 |
angioedema due | 6 |
surfactant protein | 6 |
dna methylation | 6 |
allergic mice | 6 |
nasopharyngeal relative | 6 |
activation markers | 6 |
variable immunodeficiency | 6 |
therapy program | 6 |
molecular techniques | 6 |
follicle wall | 6 |
immunoglobulin replacement | 6 |
target proteases | 6 |
kinin system | 6 |
infectious diseases | 6 |
promising approaches | 6 |
common diseases | 6 |
research nurse | 5 |
human bocavirus | 5 |
mg protein | 5 |
including il | 5 |
young adults | 5 |
major mediator | 5 |
stimulated gene | 5 |
food allergy | 5 |
increased vascular | 5 |
primary defect | 5 |
effective dose | 5 |
severely ill | 5 |
sputum sample | 5 |
neutral endopeptidase | 5 |
human microbiome | 5 |
severe angioedema | 5 |
drug administration | 5 |
antiviral activity | 5 |
cell repertoire | 5 |
human bronchial | 5 |
autosomal dominant | 5 |
aging might | 5 |
derived products | 5 |
sensitized mice | 5 |
trait meta | 5 |
rag activity | 5 |
allergic response | 5 |
sinus secretions | 5 |
angioedema without | 5 |
memory cd | 5 |
evidence suggests | 5 |
attacks may | 5 |
years old | 5 |
weight gain | 5 |
immune activation | 5 |
table vi | 5 |
inflammatory bowel | 5 |
shared genetic | 5 |
without nasal | 5 |
clinical data | 5 |
trait analysis | 5 |
covid patients | 5 |
statistical significance | 5 |
tissue kallikrein | 5 |
functional deficiency | 5 |
life questionnaire | 5 |
type immune | 5 |
acid test | 5 |
clinical outcomes | 5 |
acquired pneumonia | 5 |
significantly lower | 5 |
cell response | 5 |
mortality rates | 5 |
respiratory rate | 5 |
high plasma | 5 |
unclear whether | 5 |
clinical implications | 5 |
angioedema hereditary | 5 |
st louis | 5 |
coding region | 5 |
invasive mechanical | 5 |
among older | 5 |
asthma model | 5 |
ciliary beat | 5 |
protein levels | 5 |
disease expression | 5 |
sputum specimens | 5 |
chronic inflammatory | 5 |
safety concerns | 5 |
gene mutations | 5 |
typical symptoms | 5 |
current understanding | 5 |
medical history | 5 |
higher incidence | 5 |
cd cd | 5 |
whitney test | 5 |
plasma samples | 5 |
antiviral drugs | 5 |
cell counts | 5 |
peak flow | 5 |
first years | 5 |
tcz treatment | 5 |
acid sequence | 5 |
mutually exclusive | 5 |
atopic disease | 5 |
cytokine levels | 5 |
future research | 5 |
vascular leakage | 5 |
late tcz | 5 |
fold increased | 5 |
erythema marginatum | 5 |
hand hygiene | 5 |
glandular exocytosis | 5 |
current asthma | 5 |
virus bronchiolitis | 5 |
positive results | 5 |
candidate genes | 5 |
small number | 5 |
activating gene | 5 |
abdominal ultrasound | 5 |
skin tests | 5 |
previous study | 5 |
lower airway | 5 |
enzyme inhibitors | 5 |
severe coronavirus | 5 |
lymphoproliferative disorders | 5 |
signaling pathways | 5 |
glycosylation sites | 5 |
hyperinflammatory milieu | 5 |
patients may | 5 |
angioedema symptoms | 5 |
cell expansion | 5 |
patients undergoing | 5 |
colonic eosinophilia | 5 |
elderly population | 5 |
known hae | 5 |
angiotensin i | 5 |
leading cause | 5 |
oral contraceptives | 5 |
bowel disease | 5 |
maternal atopic | 5 |
inh plasma | 5 |
serum immunoglobulin | 5 |
taste receptors | 5 |
disorders associated | 5 |
biologic therapies | 5 |
multiplex pcr | 5 |
patients without | 5 |
blood mononuclear | 5 |
chronic asthma | 5 |
vital signs | 5 |
many studies | 5 |
deficiency angioedema | 5 |
related disorders | 5 |
host immune | 5 |
degrading aminopeptidase | 5 |
edematous swelling | 5 |
complement function | 5 |
authors note | 5 |
deficient mice | 5 |
stat activation | 5 |
angiotensin converting | 5 |
close relationship | 5 |
human beings | 5 |
estrogen therapy | 5 |
rag genes | 5 |
enzyme activity | 5 |
protective effect | 5 |
study population | 5 |
serine proteases | 5 |
exact test | 5 |
acquired deficiency | 5 |
acute bronchiolitis | 5 |
several small | 5 |
every months | 5 |
statistical analyses | 5 |
mortality rate | 5 |
ifng response | 5 |
chart review | 5 |
asthma quality | 5 |
showed increased | 5 |
ii receptor | 5 |
highly conserved | 5 |
inh levels | 5 |
later immune | 5 |
chronic respiratory | 5 |
african american | 5 |
type cytokines | 5 |
health measures | 5 |
adult asthmatic | 5 |
well known | 5 |
primary defects | 5 |
common colds | 5 |
turbinate epithelial | 5 |
may vary | 5 |
per year | 5 |
complement cascade | 5 |
mechanical trauma | 5 |
tight junction | 5 |
asymptomatic subjects | 5 |
neutrophil activation | 5 |
taken together | 5 |
circulating biomarkers | 5 |
increased airway | 5 |
investigated whether | 5 |
coronavirus pneumonia | 5 |
negative control | 5 |
severe exacerbation | 5 |
autoimmune disease | 5 |
one patient | 5 |
dna sequence | 5 |
estrogen replacement | 5 |
gene rearrangements | 5 |
broad spectrum | 5 |
european countries | 5 |
icu patients | 5 |
respiratory health | 5 |
ordinal scale | 5 |
kinin formation | 5 |
also known | 5 |
specific pathogens | 5 |
partly explain | 5 |
molecular mass | 5 |
distilled water | 5 |
bronchial asthma | 5 |
sensitive aminopeptidase | 5 |
hae caused | 5 |
wide cross | 5 |
patients compared | 5 |
high level | 5 |
transgenic rabbits | 5 |
severe influenza | 5 |
asthma research | 5 |
inh gene | 5 |
murine model | 5 |
release syndrome | 5 |
functional analysis | 5 |
rare diseases | 5 |
institutional review | 5 |
family history | 5 |
month period | 5 |
sequence analysis | 5 |
biofilm detection | 5 |
cytological grading | 5 |
rag mutation | 5 |
normal sinus | 5 |
complex traits | 5 |
inh may | 5 |
beat frequency | 5 |
treated patients | 5 |
maxillary sinus | 5 |
adult population | 5 |
attack frequency | 5 |
clinical syndrome | 5 |
mouse models | 5 |
reproductive age | 5 |
elderly might | 5 |
nasal cytology | 5 |
pulmonary function | 4 |
questions regarding | 4 |
cell development | 4 |
patient characteristics | 4 |
severe symptoms | 4 |
sinus infections | 4 |
predicted value | 4 |
recognition receptor | 4 |
viral pathogens | 4 |
human sinonasal | 4 |
lung pathology | 4 |
severe illness | 4 |
acute episodes | 4 |
therapeutic approaches | 4 |
laboratory data | 4 |
nasal symptoms | 4 |
functional assays | 4 |
asthma susceptibility | 4 |
aging study | 4 |
complement component | 4 |
swab samples | 4 |
asthma prevalence | 4 |
plasma proteins | 4 |
national institutes | 4 |
inflammatory conditions | 4 |
tissue inflammation | 4 |
mean age | 4 |
eosinophilic inflammation | 4 |
recent evidence | 4 |
requiring hospitalization | 4 |
use may | 4 |
ii interferon | 4 |
using real | 4 |
rheumatoid arthritis | 4 |
tissue damage | 4 |
neutrophilic inflammation | 4 |
mg daily | 4 |
signal transduction | 4 |
strongly associated | 4 |
clinical presentations | 4 |
patients whose | 4 |
virus inactivation | 4 |
new mutation | 4 |
turku university | 4 |
pseudomonas aeruginosa | 4 |
studies linking | 4 |
ultrasound examination | 4 |
whose angioedema | 4 |
sars coronavirus | 4 |
pathogenic viruses | 4 |
major role | 4 |
surgical emergency | 4 |
reference database | 4 |
necrosis factor | 4 |
normative aging | 4 |
symptomatic relief | 4 |
successfully treated | 4 |
dose inhaler | 4 |
multicenter prospective | 4 |
adult covid | 4 |
low prevalence | 4 |
chronic lung | 4 |
type plasminogen | 4 |
versus rsv | 4 |
abdominal symptoms | 4 |
atopic status | 4 |
hospital admissions | 4 |
abdominal hae | 4 |
helicobacter pylori | 4 |
online data | 4 |
whereas others | 4 |
similar mutations | 4 |
family member | 4 |
might predispose | 4 |
least different | 4 |
clinically proven | 4 |
regression analysis | 4 |
birth cohort | 4 |
receiving ace | 4 |
reversible airflow | 4 |
promoter sequence | 4 |
ovarian follicular | 4 |
nontemplate controls | 4 |
stimulating hormone | 4 |
allergen challenge | 4 |
bradykinin receptors | 4 |
allergic inflammation | 4 |
damaged cells | 4 |
baylor college | 4 |
ace inhibition | 4 |
human influenza | 4 |
table iv | 4 |
interferon signaling | 4 |
advancing age | 4 |
nanoparticle vaccine | 4 |
mutation detection | 4 |
patients requiring | 4 |
natural product | 4 |
clinical cytological | 4 |
per day | 4 |
known whether | 4 |
paranasal sinuses | 4 |
differential diagnosis | 4 |
lymphocyte count | 4 |
messenger rna | 4 |
lung epithelial | 4 |
microbial community | 4 |
transcription levels | 4 |
inflammatory markers | 4 |
abdominal edema | 4 |
pulmonary vascular | 4 |
asthma mortality | 4 |
myocardial infarction | 4 |
many elderly | 4 |
san diego | 4 |
acute viral | 4 |
infants hospitalized | 4 |
undergoing surgical | 4 |
linkage disequilibrium | 4 |
dual inhibitor | 4 |
clinical development | 4 |
acute lung | 4 |
lymph node | 4 |
might partly | 4 |
sequence data | 4 |
among children | 4 |
reduce mortality | 4 |
entry depends | 4 |
human respiratory | 4 |
within minutes | 4 |
respiratory diseases | 4 |
cell responses | 4 |
interferon production | 4 |
receptor signaling | 4 |
inh activity | 4 |
newly diagnosed | 4 |
received research | 4 |
long cdr | 4 |
adverse effect | 4 |
viral upper | 4 |
surgical intervention | 4 |
young patients | 4 |
twin pairs | 4 |
pulmonary changes | 4 |
phospholipid microparticles | 4 |
fvc ratio | 4 |
danazol prophylaxis | 4 |
sialic acid | 4 |
like symptoms | 4 |
wide search | 4 |
may occur | 4 |
gastroesophageal reflux | 4 |
rag proteins | 4 |
review board | 4 |
mutations resulting | 4 |
critical care | 4 |
situ hybridization | 4 |
severe complications | 4 |
although several | 4 |
pathophysiologic mechanisms | 4 |
nasal polyp | 4 |
scanning laser | 4 |
ap secretion | 4 |
recently described | 4 |
continuous variables | 4 |
cellular immune | 4 |
atopic subjects | 4 |
induced bronchiolitis | 4 |
chronic maxillary | 4 |
phage display | 4 |
latent adenoviral | 4 |
obstructive lung | 4 |
airway wall | 4 |
inflammatory disease | 4 |
life expectancy | 4 |
chemokine production | 4 |
tobacco smoke | 4 |
cell type | 4 |
bronchial hyperresponsiveness | 4 |
mrna copies | 4 |
bone mass | 4 |
likely results | 4 |
enteroviral infections | 4 |
antibiotic treatment | 4 |
bradykinin concentrations | 4 |
inh inhibits | 4 |
classic pathway | 4 |
factor ix | 4 |
immune mediator | 4 |
function testing | 4 |
requiring imv | 4 |
follicular fluid | 4 |
confocal scanning | 4 |
approximately mg | 4 |
genomic dna | 4 |
parainfluenza type | 4 |
rsv rna | 4 |
also reported | 4 |
asthmatic children | 4 |
sinus mucosal | 4 |
prospective study | 4 |
pathogenic bacteria | 4 |
vitro studies | 4 |
antimicrobial effects | 4 |
proven protease | 4 |
median time | 4 |
proteins involved | 4 |
increased serum | 4 |
physical function | 4 |
gene polymorphisms | 4 |
inhibitory effects | 4 |
physical activity | 4 |
cxcl levels | 4 |
disease burden | 4 |
quantitative trait | 4 |
cells comprise | 4 |
kininase i | 4 |
thrombin generation | 4 |
early stage | 4 |
inflammatory processes | 4 |
infectious agents | 4 |
genetic factors | 4 |
increase susceptibility | 4 |
associated diseases | 4 |
cytokine release | 4 |
controlled study | 4 |
biological activity | 4 |
may decrease | 4 |
whole genome | 4 |
sinus tissue | 4 |
statistical analysis | 4 |
blood count | 4 |
i study | 4 |
receptor expression | 4 |
remains elusive | 4 |
aged years | 4 |
functional decline | 4 |
without evidence | 4 |
severe rsv | 4 |
tlr signaling | 4 |
determined based | 4 |
laser microscopy | 4 |
even higher | 4 |
social distancing | 4 |
dataset gse | 4 |
positively correlated | 4 |
bacterial burden | 4 |
potential confounders | 4 |
race ethnicity | 4 |
clinically significant | 4 |
tongji hospital | 4 |
symptomatic patients | 4 |
multicenter study | 4 |
binding site | 4 |
mg kg | 4 |
nasal epithelium | 4 |
high concentrations | 4 |
might contribute | 4 |
adverse events | 4 |
negatively charged | 4 |
bone marrow | 4 |
inh molecule | 4 |
parainfluenza viruses | 4 |
adverse outcome | 4 |
recent years | 4 |
every weeks | 4 |
wide association | 4 |
dynein arms | 4 |
early intervention | 4 |
protein kinase | 4 |
ifit ifi | 4 |
fungal infection | 4 |
environmental interactions | 4 |
female patient | 4 |
lod score | 4 |
similar rag | 4 |
genome screens | 4 |
causes type | 4 |
statistical computing | 4 |
nucleic acids | 4 |
international hae | 4 |
pichia pastoris | 4 |
heart disease | 4 |
patients presenting | 4 |
gel electrophoresis | 4 |
complement deficiency | 4 |
genetic defect | 4 |
much higher | 4 |
mucosal samples | 4 |
serpin domain | 4 |
emergency departments | 4 |
suppl table | 4 |
demographic characteristics | 4 |
viii concentrate | 4 |
cascade systems | 4 |
growth factor | 4 |
nasal washes | 4 |
nitrogen dioxide | 4 |
also found | 4 |
longer duration | 4 |
androgen treatment | 4 |
cases compared | 4 |
mrna expression | 4 |
persistent asthma | 4 |
acute illness | 4 |
environmental exposures | 4 |
thrombocytopenic purpura | 4 |
cognitive impairment | 4 |
rhinovirus infections | 4 |
normal human | 4 |
pulmonary edema | 4 |
infancy respiratory | 4 |
significant correlation | 4 |
virus reduction | 4 |
molecular basis | 4 |
neuraminidase inhibitors | 4 |
protein expression | 4 |
care visit | 4 |
plaque psoriasis | 4 |
inflammatory diseases | 4 |
climate change | 4 |
molecular biology | 4 |
asthmatic patient | 4 |
hay fever | 4 |
viral shedding | 4 |
normal levels | 4 |
microbiota profile | 4 |
dz twins | 4 |
plasma levels | 4 |
small studies | 4 |
universal influenza | 4 |
global initiative | 4 |
one may | 4 |
antigenic concentration | 4 |
first days | 4 |
min mg | 4 |
data protection | 4 |
serum total | 4 |
induced ifng | 4 |
allergic sensitization | 4 |
nonallergic individuals | 4 |
associated inherited | 4 |
plasmin formation | 4 |
bronchodilator response | 4 |
response might | 4 |
predict asthma | 4 |
considered significant | 4 |
middle age | 4 |
interquartile range | 4 |
nh mutation | 4 |
research support | 4 |
epidemiologic studies | 4 |
year period | 4 |
old female | 4 |
new therapeutic | 4 |
infection rates | 4 |
will help | 4 |
asthma risk | 4 |
inflammatory pathways | 4 |
tyrosine kinase | 4 |
quality control | 4 |
inh serpin | 4 |
fold increase | 4 |
oc use | 4 |
common cause | 4 |
live attenuated | 4 |
asthma therapy | 4 |
severity score | 4 |
cell function | 4 |
hae patient | 4 |
taken every | 4 |
sinus epithelium | 4 |
modifier genes | 4 |
data supplement | 4 |
oxygen saturation | 4 |
confidence intervals | 4 |
nasopharyngeal airway | 4 |
hospital admission | 4 |
endothelial cell | 4 |
mediated angioedema | 4 |
postviral asthma | 4 |
intubation death | 4 |
bradykinin formation | 4 |
human complement | 4 |
recalcitrant nasal | 4 |
pcr products | 4 |
cell production | 4 |
day care | 4 |
might explain | 4 |
dose corticosteroid | 4 |
point mutations | 4 |
terminal domain | 4 |
based study | 4 |
threatening laryngeal | 4 |
health status | 4 |
house dust | 4 |
activated receptor | 4 |
cell lymphopenia | 4 |
dna vaccine | 4 |
fev fvc | 4 |
bone turnover | 4 |
results suggest | 4 |
function relationships | 4 |
min ml | 4 |
study design | 4 |
attack generation | 4 |
acute hae | 4 |
common symptom | 4 |
angioedema type | 4 |
wide variety | 4 |
low numbers | 4 |
community study | 4 |
developing angioedema | 4 |
ultrasound pattern | 4 |
rna polymerase | 4 |
matched healthy | 4 |
inh mice | 4 |
immunoreactive material | 4 |
asthma medications | 4 |
dendritic cell | 4 |
transgenic animals | 4 |
nasal airway | 4 |
infant viral | 4 |
rhinovirus illnesses | 4 |
acute wheezing | 4 |
may help | 4 |
model included | 4 |
nobel prize | 4 |
staphylococcal superantigens | 4 |
dust mites | 4 |
tlr expression | 4 |
gene anomalies | 4 |
patients admitted | 4 |
association study | 4 |
antiviral drug | 4 |
guide pa | 3 |
cytokine milieu | 3 |
future treatment | 3 |
study using | 3 |
medical information | 3 |
serum carboxypeptidase | 3 |
studies using | 3 |
depressive disorder | 3 |
maximum concentration | 3 |
immunomodulatory drugs | 3 |
i went | 3 |
cold symptoms | 3 |
clinical observations | 3 |
either hrv | 3 |
glandular secretion | 3 |
patients taking | 3 |
became negative | 3 |
correlation analysis | 3 |
recurrent bacterial | 3 |
activating factor | 3 |
patients reported | 3 |
acute phase | 3 |
ct scan | 3 |
occurred less | 3 |
increased bacterial | 3 |
cysteinyl leukotriene | 3 |
peak expiratory | 3 |
ari group | 3 |
truncated rag | 3 |
fungal allergens | 3 |
goblet cell | 3 |
frozen plasma | 3 |
steroid use | 3 |
zlb behring | 3 |
performance battery | 3 |
plasma concentrate | 3 |
plasma cascade | 3 |
expiratory flow | 3 |
chemokine rantes | 3 |
might well | 3 |
cause exacerbation | 3 |
significantly negatively | 3 |
also reduce | 3 |
mean difference | 3 |
patient education | 3 |
genetic defects | 3 |
likelihood ratio | 3 |
fixed airflow | 3 |
quantitative pcr | 3 |
currently known | 3 |
per sample | 3 |
many questions | 3 |
working group | 3 |
largely unknown | 3 |
eosinophils hpf | 3 |
negative bacterial | 3 |
also thank | 3 |
human alveolar | 3 |
tables i | 3 |
extrinsic pathway | 3 |
least parent | 3 |
kunitz domain | 3 |
certain degree | 3 |
commercially available | 3 |
several decades | 3 |
may regulate | 3 |
human genome | 3 |
different types | 3 |
psoriasis receiving | 3 |
study performed | 3 |
airway infection | 3 |
cell populations | 3 |
sole hrv | 3 |
cystic fibrosis | 3 |
allergic disorders | 3 |
copy number | 3 |
allergy skin | 3 |
polymerase chain | 3 |
genetic correlations | 3 |
negative bacteria | 3 |
virus species | 3 |
prophylactic use | 3 |
fish oil | 3 |
hae association | 3 |
response translates | 3 |
haemolytic anaemia | 3 |
enrolled infants | 3 |
asymptomatic infection | 3 |
cell proliferation | 3 |
severe anxiety | 3 |
predispose patients | 3 |
aae type | 3 |
airway samples | 3 |
underlying defects | 3 |
cleaved hk | 3 |
rhinosinusitis biofilms | 3 |
receptor blockers | 3 |
heat shock | 3 |
performed significantly | 3 |
therapeutic interventions | 3 |
inhibitor complexes | 3 |
advanced age | 3 |
notably lactoferrin | 3 |
patients date | 3 |
insurance type | 3 |
induced wheezing | 3 |
might provide | 3 |
bactericidal permeability | 3 |
first described | 3 |
relatively low | 3 |
positive skin | 3 |
retrospective observational | 3 |
nasal endoscopy | 3 |
microbial balance | 3 |
effective means | 3 |
million people | 3 |
first time | 3 |
increased wheezing | 3 |
african americans | 3 |
routine methods | 3 |
chicken soup | 3 |
novo mutations | 3 |
many challenges | 3 |
cxcl protein | 3 |
medical center | 3 |
unrelated patients | 3 |
infectious disease | 3 |
upper limit | 3 |
cell rna | 3 |
nasopharyngeal swab | 3 |
airways reactivity | 3 |
driven genes | 3 |
recurrent wheezing | 3 |
control test | 3 |
containing oc | 3 |
acute edematous | 3 |
recent research | 3 |
oxidative stress | 3 |
specific virus | 3 |
also detected | 3 |
observational studies | 3 |
often requires | 3 |
develop angioedema | 3 |
requiring oxygen | 3 |
subjects infected | 3 |
among african | 3 |
intolerant asthma | 3 |
individual variation | 3 |
adenovirus might | 3 |
several proteases | 3 |
neutrophil elastase | 3 |
negative correlation | 3 |
enkephalin degrading | 3 |
preventing acute | 3 |
nonhistaminergic angioedema | 3 |
truncating rag | 3 |
antiviral immunity | 3 |
ige antibodies | 3 |
submucosal mixed | 3 |
leukocyte elastase | 3 |
human volunteers | 3 |
known causes | 3 |
persistent respiratory | 3 |
gene sequence | 3 |
room air | 3 |
population sample | 3 |
authors suggest | 3 |
early tcz | 3 |
future investigation | 3 |
health policies | 3 |
types i | 3 |
one hundred | 3 |
dimensional model | 3 |
gestational age | 3 |
causal role | 3 |
candidate mediator | 3 |
may contribute | 3 |
longitudinal study | 3 |
typing assay | 3 |
superoxide dismutase | 3 |
reference values | 3 |
electronic medical | 3 |
studies reported | 3 |
ang ii | 3 |
severe outcomes | 3 |
environmental impacts | 3 |
negative regulator | 3 |
killer cells | 3 |
prophylactic therapy | 3 |
normal concentrations | 3 |
occur without | 3 |
ng ml | 3 |
i interferon | 3 |
elevated serum | 3 |
missing data | 3 |
routine laboratory | 3 |
cumulative dose | 3 |
crs remains | 3 |
different mutations | 3 |
interstitial lung | 3 |
elevated plasma | 3 |
complex interplay | 3 |
large deletions | 3 |
weighted unifrac | 3 |
immunocompetent subjects | 3 |
human il | 3 |
vascular endothelial | 3 |
chromosomal region | 3 |
enhances virus | 3 |
strong genetic | 3 |
functional limitations | 3 |
randomized trial | 3 |
cell recruitment | 3 |
increases tmprss | 3 |
respiratory questionnaire | 3 |
abdominal manifestations | 3 |
i interferons | 3 |
developed severe | 3 |
asthma management | 3 |
human lung | 3 |
abstract background | 3 |
experimental infection | 3 |
yield insights | 3 |
us hae | 3 |
participants demonstrate | 3 |
chronic hepatitis | 3 |
will require | 3 |
subsequent childhood | 3 |
test reactivity | 3 |
year old | 3 |
elderly asthma | 3 |
association studies | 3 |
dependent angioedema | 3 |
patients first | 3 |
infant hrv | 3 |
based algorithms | 3 |
natural products | 3 |
asthmatic response | 3 |
aureus biofilm | 3 |
normal airway | 3 |
synergistic effect | 3 |
rhinovirus replication | 3 |
angioedema occurred | 3 |
tcz showed | 3 |
different disease | 3 |
passive immunization | 3 |
ige production | 3 |
women whose | 3 |
term danazol | 3 |
patients clinical | 3 |
reduce kinin | 3 |
provide insights | 3 |
inhibitory capacity | 3 |
years ago | 3 |
extensively studied | 3 |
kinin generation | 3 |
bal fluid | 3 |
relative rate | 3 |
also important | 3 |
factor xiif | 3 |
way anova | 3 |
active site | 3 |
chemokine levels | 3 |
delayed viral | 3 |
patients received | 3 |
differential regulation | 3 |
increased incidence | 3 |
total number | 3 |
younger adults | 3 |
otitis media | 3 |
predictive accuracy | 3 |
gov grants | 3 |
tight junctions | 3 |
minimum effective | 3 |
last accessed | 3 |
infant infection | 3 |
infection effect | 3 |
extremity function | 3 |
complement pathway | 3 |
analysis revealed | 3 |
vasopeptidase inhibition | 3 |
creatine kinase | 3 |
respiratory support | 3 |
significantly associated | 3 |
office visits | 3 |
also provide | 3 |
expression compared | 3 |
microbial dna | 3 |
negative staphylococcus | 3 |
virus detection | 3 |
developed recurrent | 3 |
school children | 3 |
skin inflammation | 3 |
exon deletions | 3 |
viral bronchiolitis | 3 |
may play | 3 |
app activity | 3 |
acute symptoms | 3 |
inhibitory activity | 3 |
using pcr | 3 |
microbiome project | 3 |
induced airway | 3 |
study inclusion | 3 |
patient developed | 3 |
translates respiratory | 3 |
chronic enteroviral | 3 |
infection might | 3 |
specific treatment | 3 |
pandemic decrease | 3 |
residual recombinase | 3 |
unstimulated pbmcs | 3 |
phase iii | 3 |
higher likelihood | 3 |
elastic recoil | 3 |
attack rate | 3 |
mild symptoms | 3 |
normal complement | 3 |
laryngeal attacks | 3 |
sheep model | 3 |
response patterns | 3 |
affected family | 3 |
early onset | 3 |
resistant aminopeptidase | 3 |
diagnosing asthma | 3 |
angioedema plasma | 3 |
first component | 3 |
oxygen tension | 3 |
also observed | 3 |
mg dl | 3 |
live dead | 3 |
mobility disability | 3 |
higher frequency | 3 |
asthma among | 3 |
yet another | 3 |
wheezing children | 3 |
regular medical | 3 |
leukocyte antigen | 3 |
examined whether | 3 |
significant increase | 3 |
alkylated androgens | 3 |
experimentally induced | 3 |
rhinosinusitis expression | 3 |
deficient patients | 3 |
may explain | 3 |
persistent infection | 3 |
expression levels | 3 |
biologically active | 3 |
research suggests | 3 |
rhinovirus rna | 3 |
type littermates | 3 |
blood pressure | 3 |
bacterial lysate | 3 |
nasal spray | 3 |
allergic responses | 3 |
active complement | 3 |
muscle weakness | 3 |
mitigating disease | 3 |
within days | 3 |
mononuclear cell | 3 |
ltc synthase | 3 |
also performed | 3 |
distinct nasopharyngeal | 3 |
beneficial effect | 3 |
asthma might | 3 |
distinct genetic | 3 |
low cd | 3 |
recombinant interferon | 3 |
inh antigenic | 3 |
lactate dehydrogenase | 3 |
diagnostic tests | 3 |
pcr analysis | 3 |
irregular menstruation | 3 |
produce ifn | 3 |
occur less | 3 |
genetic analysis | 3 |
nonsteroidal anti | 3 |
cell markers | 3 |
also showed | 3 |
even without | 3 |
neutralizing antibody | 3 |
cd cells | 3 |
virus fusion | 3 |
profuse diarrhea | 3 |
replicative senescence | 3 |
factor binding | 3 |
register will | 3 |
mismatch analysis | 3 |
goblet cells | 3 |
acute infection | 3 |
infection clinical | 3 |
complement measurements | 3 |
must also | 3 |
another group | 3 |
receptor blockade | 3 |
serous cells | 3 |
previously reported | 3 |
antifungal treatment | 3 |
reply date | 3 |
often associated | 3 |
fungal dna | 3 |
preschool children | 3 |
older women | 3 |
terminal truncated | 3 |
control specimens | 3 |
per patient | 3 |
six patients | 3 |
comorbid illnesses | 3 |
multivariable analysis | 3 |
prevent functional | 3 |
sequence variants | 3 |
gene transcription | 3 |
total lymphocyte | 3 |
nervous system | 3 |
will environmental | 3 |
arterial oxygen | 3 |
lower airways | 3 |
positive patients | 3 |
great interest | 3 |
data suggest | 3 |
whereas additional | 3 |
leukotriene production | 3 |
allergic angioedema | 3 |
dr expression | 3 |
pulmonary inflammation | 3 |
citrated plasma | 3 |
attack per | 3 |
available data | 3 |
hae treatment | 3 |
distinct immunologic | 3 |
manufacturing procedure | 3 |
virus entry | 3 |
lower prevalence | 3 |
nursing home | 3 |
fibrinolytic system | 3 |
aged animals | 3 |
laboratory criteria | 3 |
acute lower | 3 |
related adverse | 3 |
future studies | 3 |
missing factor | 3 |
may become | 3 |
pathways might | 3 |
null mutations | 3 |
demonstrate lower | 3 |
pediatric hae | 3 |
clinical picture | 3 |
critical role | 3 |
mbl deficiency | 3 |
inh antigen | 3 |
global health | 3 |
drosophila species | 3 |
plasma pool | 3 |
structural changes | 3 |
leukocyte subsets | 3 |
host cell | 3 |
us children | 3 |
specific cells | 3 |
large epidemiologic | 3 |
high sensitivity | 3 |
severe chronic | 3 |
patient association | 3 |
illness onset | 3 |
dose danazol | 3 |
decreased ifn | 3 |
bone mineral | 3 |
risk children | 3 |
human immunodeficiency | 3 |
terminal part | 3 |
associated serine | 3 |
less severe | 3 |
dental surgery | 3 |
inh preparations | 3 |
diagnosed patients | 3 |
stat phosphorylation | 3 |
hae register | 3 |
exact mid | 3 |
restoring host | 3 |
exaggerated response | 3 |
february th | 3 |
lung inflammation | 3 |
escherichia coli | 3 |
stranded rna | 3 |
files pa | 3 |
antiviral strategies | 3 |
rag deficiency | 3 |
clinical research | 3 |
pathology database | 3 |
viral properties | 3 |
icu group | 3 |
viral susceptibility | 3 |
low plasma | 3 |
adaptive immunity | 3 |
cross laps | 3 |
increasing evidence | 3 |
case report | 3 |
neutrophilic asthma | 3 |
diagnostic tool | 3 |
lrti subgroup | 3 |
human monocytes | 3 |
will also | 3 |
chain reaction | 3 |
using molecular | 3 |
airway diseases | 3 |
induce leakage | 3 |
several patients | 3 |
cells may | 3 |
reported cases | 3 |
performance measures | 3 |
receiving biologic | 3 |
ari severity | 3 |
rhinoviral infection | 3 |
cov infection | 3 |
clinical practice | 3 |
episodes occurred | 3 |
receptor ace | 3 |
respiratory function | 3 |
induced interferon | 3 |
healthy children | 3 |
proportional odds | 3 |
approximately kd | 3 |
asked whether | 3 |
test system | 3 |
blood products | 3 |
nasopharyngeal microbiome | 3 |
virus shedding | 3 |
beckman coulter | 3 |
lymphoid cells | 3 |
current evidence | 3 |
drug discovery | 3 |
idiopathic nonhistaminergic | 3 |
currently unknown | 3 |
serum igg | 3 |
cells per | 3 |
high affinity | 3 |
plunc protein | 3 |
adverse clinical | 3 |
low functional | 3 |
response toward | 3 |
bacterial pathogens | 3 |
cell tolerance | 3 |
highly specific | 3 |
activation via | 3 |
blood cell | 3 |
flow lability | 3 |
plasma protein | 3 |
exogenous estrogen | 3 |
chemokine gene | 3 |
individual patient | 3 |
hepatocellular adenoma | 3 |
medical costs | 3 |
autoimmune haemolytic | 3 |
just like | 3 |
measured using | 3 |
survival analysis | 3 |
ighj gene | 3 |
cardiac injury | 3 |
rank sum | 3 |
complement values | 3 |
terminal truncation | 3 |
human blood | 3 |
elder age | 3 |
liver function | 3 |
nasal lavages | 3 |
decrease allergic | 3 |
lower limits | 3 |
common prophylaxis | 3 |
severe outcome | 3 |
pcr assay | 3 |
gland cells | 3 |
symptom onset | 3 |
alveolar macrophages | 3 |
mucociliary function | 3 |
highly effective | 3 |
recurrent abdominal | 3 |
bone metabolism | 3 |
gene product | 3 |
closely resemble | 3 |
hypovolemic shock | 3 |
maternal race | 3 |
hae patients | 3 |
idiopathic thrombocytopenic | 3 |
clinical response | 3 |
trophic unit | 3 |
table viii | 3 |
knockout mice | 3 |
cell metaplasia | 3 |
helper type | 3 |
laboratory parameters | 3 |
adequate immunoglobulin | 3 |
intercellular adhesion | 3 |
main clinical | 3 |
clinical relevance | 3 |
viral cultivation | 3 |
results indicate | 3 |
severe clinical | 3 |
unadjusted analyses | 3 |
new york | 3 |
chromogenic assay | 3 |
induced protein | 3 |
standardized incidence | 3 |
high asthma | 3 |
bound aminopeptidases | 3 |
young asthmatic | 3 |
kinin metabolism | 3 |
immune reaction | 3 |
unproductive rearrangements | 3 |
horizontal pleiotropy | 3 |
wilcoxon rank | 3 |
autoimmune acquired | 3 |
cell signaling | 3 |
disease onset | 3 |
mild asthma | 3 |
estrogen concentrations | 3 |
temperomandibular pain | 3 |
especially important | 3 |
inhibitor alone | 3 |
ribosomal rna | 3 |
early stages | 3 |
highly relevant | 3 |
viral culture | 3 |
inhibitor activity | 3 |
mechanisms may | 3 |
primary ciliary | 3 |
care use | 3 |
receptor system | 3 |
electron microscopy | 3 |
pulmonary rehabilitation | 3 |
oral contraceptive | 3 |
might reflect | 3 |
acquired deficiencies | 3 |
results demonstrate | 3 |
adults identify | 3 |
prove useful | 3 |
first step | 3 |
innate inflammatory | 3 |
lymphocyte counts | 3 |
microscopy evidence | 3 |
three patients | 3 |
linked agammaglobulinemia | 3 |
bradykinin concentration | 3 |
novel mutations | 3 |
less effective | 3 |
european commission | 3 |
mutation analysis | 3 |
data collection | 3 |
throat swabs | 3 |
inhibitor deficiencies | 3 |
significantly worse | 3 |
maximum lifespan | 3 |
direct sequencing | 3 |
international study | 3 |
body mass | 3 |
allergic patients | 3 |
crs undergoing | 3 |
mucous cells | 3 |
chemokine receptor | 3 |
cold air | 3 |
nonhomologous end | 3 |
adhesion molecule | 3 |
taking oral | 3 |
safety parameters | 3 |
angioedema activation | 3 |
patients might | 3 |
preliminary report | 3 |
dominant microbiota | 3 |
also seen | 3 |
nk cells | 3 |
sag motif | 3 |
life time | 3 |
inversely correlated | 3 |
safety profile | 3 |
infected human | 3 |
induced lung | 3 |
mg per | 3 |
cross lap | 3 |
economic burden | 3 |
cytokine secretion | 3 |
will provide | 3 |
effective treatment | 3 |
therapeutic targets | 3 |
asthma education | 3 |
acute airway | 3 |
periovulatory period | 3 |
mechanisms leading | 3 |
humoral immune | 3 |
ischemic heart | 3 |
face masks | 3 |
recombinant protein | 3 |
olfactory dysfunction | 3 |
cardiac involvement | 3 |
grade ccg | 3 |
host inflammatory | 3 |
gene causes | 3 |
immature neutrophils | 3 |
surface markers | 3 |
rna viruses | 3 |
primary outcome | 3 |
recently found | 3 |
clinical manifestation | 3 |
induced activation | 3 |
anaerobic bacteria | 3 |
dry cough | 3 |
like particles | 3 |
based chromogenic | 3 |
myeloid cells | 3 |
old children | 3 |
adverse reactions | 3 |
intravenous immunoglobulin | 3 |
grants guide | 3 |
whereas levels | 3 |
study also | 3 |
fatty acids | 3 |
surgical outcomes | 3 |
saline challenge | 3 |
proinflammatory cytokine | 3 |
rna sequencing | 3 |
cutting edge | 3 |
molecular typing | 3 |
genetic basis | 3 |
increased sensitivity | 3 |
first attack | 3 |
increased severity | 3 |
respiratory system | 3 |
proteinase inhibitor | 3 |
nanoparticle vaccines | 3 |
dental procedures | 3 |
potential risk | 3 |
latter study | 3 |
previous reports | 3 |
american academy | 3 |
outcome variable | 3 |
angioedema treated | 3 |
foster city | 3 |
respiratory morbidity | 3 |
children hospitalized | 3 |
assay range | 3 |
clinical decision | 3 |
mixed glands | 3 |
medication use | 3 |
affected individuals | 3 |
subsequently processed | 3 |
viruses might | 3 |
persistent activation | 3 |
specific genes | 3 |
recognition receptors | 3 |
cell composition | 3 |
bm mononuclear | 3 |
angioedema generation | 3 |
adjusted relative | 3 |
mesenchymal trophic | 3 |
markedly elevated | 3 |
negative likelihood | 3 |
prospective studies | 3 |
without urticaria | 3 |
cell expression | 3 |
internal medicine | 3 |
tumor necrosis | 3 |
marco cicardi | 3 |
health systems | 3 |
performed using | 3 |
deficiency workshops | 3 |
rehabilitation program | 3 |
spearman correlation | 3 |
eosinophil cytolysis | 3 |
older men | 3 |
data indicate | 3 |
edema episodes | 3 |
ciliary dyskinesia | 3 |
genes associated | 3 |
propidium iodide | 3 |
basal condition | 3 |
possible role | 3 |
cultured epithelial | 3 |
human leukocyte | 3 |
nonenveloped viruses | 3 |
viral proteins | 3 |
mg dx | 3 |
total serum | 3 |
incidence ratios | 3 |
antibiotic treatments | 3 |
allergy sensitization | 3 |
multinomial logistic | 3 |
following sections | 3 |
term hae | 3 |
interferon response | 3 |
peak production | 3 |
mutations result | 3 |
current study | 3 |
functionally active | 3 |
constitutively expressed | 3 |
physiological changes | 3 |
triage tool | 3 |
nasal cavity | 3 |
well suited | 3 |
dust mite | 3 |
increasing protein | 3 |
consistent finding | 3 |
acting bronchodilator | 3 |
delayed menarche | 3 |
normal individuals | 3 |
rat model | 3 |
asthma subtypes | 3 |
staphylococcus species | 3 |
life predict | 3 |
allergic individuals | 3 |
therapeutic options | 3 |
term treatment | 3 |
signal transducer | 3 |
york city | 3 |
fusion protein | 3 |
sulfur dioxide | 3 |
increase kinin | 3 |
cells might | 3 |
expired air | 3 |
rhinosinusitis bacterial | 3 |
low number | 3 |
starting oc | 3 |
shock protein | 3 |
mrna production | 3 |
elderly adults | 3 |
terminal phe | 3 |
unique sequences | 3 |
severe case | 3 |
greater risk | 3 |
rag mouse | 3 |
among subjects | 3 |
lower limit | 3 |
written informed | 3 |
estrogencontaining medications | 3 |
short physical | 3 |
soluble cd | 3 |
growth factors | 3 |
virus vaccine | 3 |
lt receptor | 3 |
irreversible airflow | 3 |
chemokine expression | 3 |
current investigation | 3 |
health consequences | 3 |
maternal smoking | 3 |
experimental models | 3 |
chest tightness | 3 |
major depressive | 3 |
significantly different | 3 |
human ovarian | 3 |
unscheduled health | 3 |
protease specificity | 3 |
subjects asthma | 3 |
innate pattern | 3 |
bronchial reactivity | 3 |
host responses | 3 |
disease control | 3 |
mucosal surface | 3 |
endotracheal intubation | 3 |
th cells | 3 |
jk genes | 3 |
also analyzed | 3 |
higher doses | 3 |
might account | 3 |
care utilization | 3 |
lung dendritic | 3 |
laboratory analyses | 3 |
molecular characterization | 3 |
studies showing | 3 |
positive allergy | 3 |
fresh frozen | 3 |
clinical information | 3 |
uncontrolled activation | 3 |
sample collection | 3 |
oedema acquired | 3 |
bromide nasal | 3 |
data capture | 3 |
different viral | 3 |
particulate matter | 3 |
also includes | 3 |
antagonist eritoran | 3 |
ipratropium bromide | 3 |
rhinosinusitis patients | 3 |
secretory leukocyte | 3 |
twice weekly | 3 |
ethnically diverse | 3 |
weeks later | 3 |
type cytokine | 3 |
classic hae | 3 |
mucosal inflammation | 3 |
decision making | 3 |
mycobacterium avium | 3 |
controlled clinical | 3 |
dna vaccines | 3 |
indoor air | 3 |
may persist | 3 |
nasal challenge | 3 |
louis site | 3 |
seasonal influenza | 3 |
terminal truncating | 3 |
angioedema treatment | 3 |
transgenic rhc | 3 |
asthma attacks | 3 |
test result | 3 |
risk score | 3 |
system proteases | 3 |
intestinal epithelial | 3 |
patient populations | 3 |
incidence rates | 3 |
different stages | 3 |
hae results | 3 |
stop codon | 3 |
nonadherent cells | 3 |
distancing due | 3 |
surface antigen | 3 |
pulmonary dysfunction | 3 |
seasonal allergic | 3 |
treatments might | 3 |
might lead | 3 |
markedly higher | 3 |
confidence interval | 3 |
corticosteroid therapy | 2 |
producing cells | 2 |
current knowledge | 2 |
novel rsv | 2 |
later development | 2 |
plasma pools | 2 |
normal saline | 2 |
controller medication | 2 |
also well | 2 |
correlation coefficients | 2 |
alanine aminopeptidase | 2 |
plus cigarette | 2 |
increased numbers | 2 |
inflammation process | 2 |
another important | 2 |
allergic reaction | 2 |
ang i | 2 |
severe gi | 2 |
multiplex identifier | 2 |
collaborative study | 2 |
jkik lb | 2 |
subsequent wheezing | 2 |
asthma severity | 2 |
another consistent | 2 |
detectable virus | 2 |
karen binkley | 2 |
negative regulation | 2 |
vaginal delivery | 2 |
bradykinin type | 2 |
clinical study | 2 |
org summarizes | 2 |
diffusing capacity | 2 |
rsv induction | 2 |
inhaling heated | 2 |
patient group | 2 |
mechanistic role | 2 |
eosin staining | 2 |
human herpesvirus | 2 |
mu mg | 2 |
contact information | 2 |
nasal eosinophilia | 2 |
broadly neutralizing | 2 |
igkj genes | 2 |
dmbt interacts | 2 |
comparing nonsevere | 2 |
synthetic kunitz | 2 |
diagnosed asthma | 2 |
spike glycoprotein | 2 |
abs responses | 2 |
model human | 2 |
month prior | 2 |
infant bronchiolitis | 2 |
versus older | 2 |
sensing molecule | 2 |
viral rna | 2 |
preoperative prophylactic | 2 |
antibody formation | 2 |
cyproterone acetate | 2 |
th week | 2 |
potential therapeutic | 2 |
table xvii | 2 |
mycophenolate mofetil | 2 |
lung damage | 2 |
precipitating factors | 2 |
femoral neck | 2 |
pilot study | 2 |
sdbj ca | 2 |
class ii | 2 |
functional concentration | 2 |
among women | 2 |
natural colds | 2 |
meso scale | 2 |
leukocyte proteinase | 2 |
cytokines associated | 2 |
membrane oxygenation | 2 |
organ dysfunction | 2 |
similar procedures | 2 |
airway cytokines | 2 |
bradykinin degradation | 2 |
factors might | 2 |
trial conducted | 2 |
induces expression | 2 |
less clear | 2 |
maternal atopy | 2 |
iv crq | 2 |
separate analyses | 2 |
healthy donors | 2 |
group compared | 2 |
ige receptor | 2 |
multicentre study | 2 |
serious consequences | 2 |
descriptive study | 2 |
type natriuretic | 2 |
intranasal amphotericin | 2 |
strong biomarker | 2 |
lead active | 2 |
certain viruses | 2 |
several adverse | 2 |
total population | 2 |
viral nsp | 2 |
available measures | 2 |
transmembrane protease | 2 |
comparative study | 2 |
edematous attack | 2 |
disease prevalence | 2 |
cell secretion | 2 |
oseltamivir use | 2 |
start site | 2 |
production process | 2 |
provides evidence | 2 |
contact phase | 2 |
damp indoor | 2 |
rsv bronchiolitis | 2 |
causative factor | 2 |
polyp tissues | 2 |
autoimmune cytopenias | 2 |
human pathogens | 2 |
rare cases | 2 |
high fraction | 2 |
hierarchical clustering | 2 |
guanine nucleotide | 2 |
care attendance | 2 |
onset scid | 2 |
binding pocket | 2 |
disease pathophysiologic | 2 |
nasopharyngeal haemophilus | 2 |
mg methacholine | 2 |
worsening asthma | 2 |
pancreatic region | 2 |
effective virus | 2 |
gene mutation | 2 |
experimental model | 2 |
acute myocardial | 2 |
concentrate twice | 2 |
active kallikrein | 2 |
pasteurization procedure | 2 |
threatening attacks | 2 |
well chamber | 2 |
nonallergic subjects | 2 |
immune deficiency | 2 |
lower extremities | 2 |
ct abnormalities | 2 |
serum angiotensin | 2 |
viral binding | 2 |
local hyperthermia | 2 |
socs haploinsufficiency | 2 |
subcutaneous edema | 2 |
frequently resistant | 2 |
late onset | 2 |
medical staff | 2 |
prevent acute | 2 |
rich inflammation | 2 |
estrogen regulation | 2 |
lifetime history | 2 |
least patient | 2 |
type asthma | 2 |
models included | 2 |
unsupervised hierarchical | 2 |
new drug | 2 |
side effect | 2 |
racial differences | 2 |
shs exposure | 2 |
preovulatory follicle | 2 |
biomarker association | 2 |
environmental drivers | 2 |
infections caused | 2 |
many possible | 2 |
despite severe | 2 |
hae typically | 2 |
derived neurovirulent | 2 |
prognostic value | 2 |
dna rearrangements | 2 |
may yield | 2 |
underlying mechanism | 2 |
serine nasal | 2 |
identification document | 2 |
large amount | 2 |
coronavirus hcov | 2 |
preferential use | 2 |
underlying defect | 2 |
young syndrome | 2 |
dna extraction | 2 |
control levels | 2 |
smaller animals | 2 |
maximum mg | 2 |
medical resources | 2 |
antimicrobial peptide | 2 |
diseases traits | 2 |
lymphocyte blood | 2 |
receptor agonists | 2 |
medical record | 2 |
patients provided | 2 |
per well | 2 |
ifit ifit | 2 |
causal relationship | 2 |
achieve satisfactory | 2 |
commonly caused | 2 |
low albumin | 2 |
pivotal role | 2 |
patients inhaling | 2 |
produced mainly | 2 |
induced ifn | 2 |
severe immunopathology | 2 |
edema may | 2 |
patients underwent | 2 |
acute infections | 2 |
stranded dna | 2 |
icu treatment | 2 |
decreased mortality | 2 |
transplant recipients | 2 |
dependent complement | 2 |
specific cd | 2 |
weight development | 2 |
current treatment | 2 |
classified women | 2 |